Imagion Biosystems Limited has lodged Appendix 4G “Key to Disclosures, Corporate Governance Council Principles and Recommendations” with the Australian Securities Exchange. Read Appendix 4G and Corporate Governance Statement.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
July 15, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging